Annals of Emergency Medicine
Volume 51, Issue 5 , Pages 571-578, May 2008

Acutely Decompensated Heart Failure in a County Emergency Department: A Double-Blind Randomized Controlled Comparison of Nesiritide Versus Placebo Treatment

  • Adam H. Miller, MD, MSc

      Affiliations

    • Department of Surgery/Division of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX
    • Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX
    • Corresponding Author InformationAddress for reprints: Adam H. Miller, MD, MSc, Department of Surgery, Division of Emergency Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8579; 214-648-2965, fax 214-648-8243
  • ,
  • Shameem Nazeer, MD

      Affiliations

    • Department of Surgery/Division of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • ,
  • Paul Pepe, MD, MPH

      Affiliations

    • Department of Surgery/Division of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • ,
  • Barbi Estes, RN

      Affiliations

    • Department of Surgery/Division of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • ,
  • April Gorman, MS

      Affiliations

    • Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX
  • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.

published online 28 February 2008.

Study objective

Acutely decompensated congestive heart failure is a major cause of emergency department (ED) visits in county hospitals. This often underserved population has a high rate of return visits to the ED for heart failure. Nesiritide has been demonstrated to relieve symptoms of acutely decompensated congestive heart failure. We examined the effect of an 8-hour infusion of nesiritide on the composite of return to the ED or hospitalization at 30 days.

Methods

A prospective, randomized, double-blinded, placebo-controlled trial of nesiritide plus protocol-specified standard therapy versus standard therapy done in the ED for acutely decompensated congestive heart failure.

Results

One hundred one patients were randomized during a 16-month enrollment period. Sixty-six percent of the patients were men and 34% were women. Fifty-six percent were black; all patients had New York Heart Association class II to IV heart failure and most had dyspnea at rest or with minimal exertion. Complete follow-up data were available in 97 of 101 patients. After the 8-hour treatment period, acute symptom relief was experienced in 95.7% of the nesiritide group (95% confidence interval [CI] 88.9% to 100%) versus 86.8% of the placebo group (95% CI 72% to 98.9%), with an absolute difference between the 2 groups of 8.9% (95% CI –3.3% to 24.2%). Diuresis was similar between the 2 groups, but hypotension occurred more frequently in the nesiritide-treated group. The primary outcome measure of return visit to the ED or hospitalization at 30 days was higher for nesiritide (41.5%) than placebo (39.6%; absolute difference 1.9%; 95% CI –17.2% to 21.1%). There was only 1 death. No measurable change in renal function was observed.

Conclusion

Administration of nesiritide for acutely decompensated congestive heart failure in a county ED was no better than standard therapy alone for return to the ED or hospitalization at 30 days.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supervising editor: Judd E. Hollander, MD

 Author contributions: AHM and SN obtained institutional review board approval. AHM, SN, and BE collected data. AHM, BE, AP, and CY analyzed data. AHM and AP conducted the statistical analysis. AHM, PP, and CWY developed the article. AHM takes responsibility for the paper as a whole.

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. This project was supported by grant number KL2RR024983 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR or NIH. This study was an investigator-initiated protocol, independently designed, initiated, supervised and analyzed by the investigators but funded by an unrestricted research grant from Scios, Inc. CWY is a consultant for GlaxoSmithKline, Scios, Inc., NitroMred, Medtronic, AstraZeneca, Otsuka and has received grants and research support from GlaxoSmithKline, Scios Inc., NitroMed, and Medtronic. CWY has also received CHF Fellowship salary support from Medtronic and Scios, Inc. CWY is on the speaker's bureau for GlaxoSmithKline and Novartis. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.

 Publication date: Available online March 4, 2008.

PII: S0196-0644(07)01852-5

doi:10.1016/j.annemergmed.2007.12.003

Refers to article:

  • Can We Improve How We Treat Patients With Heart Failure in the Emergency Department? , 17 March 2008

    Deborah B. Diercks
    Annals of Emergency Medicine May 2008 (Vol. 51, Issue 5, Pages 583-584)

Annals of Emergency Medicine
Volume 51, Issue 5 , Pages 571-578, May 2008